Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 1999

View Archived Issues

Aviron: Q4 1998 highlights

NeoRx: Q4 1998 highlights

Viragen: Q2 1998 highlights

Agouron solves structure of key target for drugs to block angiogenesis

Hemosol successfully completes phase II trial of Hemolink in CABG patients

Uncompetitive NMDA antagonists show improved efficacy in Parkinson's disease models

Novel AD and metabolic syndrome targets as focus of Exelixis and P&U collaboration

Spotlight on agents for peripheral vascular disease

New anticancer agents from LG Chemical inhibit farnesyltransferase

Antithrombotic P2T antagonists in development at Astra

Muscarinic receptor modulators for psychotic disorders patented by Lilly

Bupropion more effective than nicotine patches in smoking cessation therapy

Merck discloses novel endothelin receptor antagonists

Chemokine receptor modulators from Merck & Co. described in recent patent literature

Cyclooxygenase-inhibitory indoles under study at Pfizer

Texas Biotechnology: Q4 and year-end 1998 results

Na+/Ca2+ exchange inhibitor provides effective neuroprotection in vitro

Findings from burn study demonstrate advantage of Apligraf + autograft versus autograft alone

Study suggests potential of MS-325 in blood pool imaging

diaDexus's first diagnostic product licensed to SmithKline Beecham unit

Pharmacia & Upjohn and Centocor to copromote Fragmin in unstable angina

Bio-Technology General receives added patent protection for novel anticoagulant

FDA approves controlled-release form of popular antidepressant

North American Vaccine adds new product to R&D pipeline; U.S. patent issues

Xenova reveals structure of P-gp-mediated MDR modulators, including clinical compound XR-9576

Microbial metabolite inhibits ICAM-1/LFA-1-mediated cell adhesion

Microbial fatty acid enhances endothelial cell fibrinolytic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...